This is a comment by Nicolas ANDRE from the Department of Pediatric Hematology and Oncology, Hôpital de La Timone, AP-HM, the UMR Inserm 1068, CNRS UMR 7258, AixMarseille Université U105, Marseille Cancer Research Center (CRCM) and Metronomics Global Health Initiative,Marseille, France published in Pediatric Blood and Cancer
The special report from Slotkin and Meyer regarding the question of the schedules of administration of irinotecan for the treatment of Ewing sarcoma1 was of great (…)